scholarly journals Successful determination of imatinib dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction.

Author(s):  
Ryosuke Nakahara ◽  
Takahiro Sumimoto ◽  
Ryota Tanaka ◽  
Masao Ogata ◽  
Hiroki Itoh

Imatinib is used as first-line treatment for chronic myeloid leukemia (CML) even in patients with impaired renal function. We successfully used therapeutic drug monitoring to determine the dose for re-administration of imatinib in a CML patient who initiated dialysis for acute renal dysfunction associated with the initial imatinib therapy.

2021 ◽  
Vol 18 (2) ◽  
Author(s):  
Sneha Tandon ◽  
Raviraj Deshpande ◽  
Gaurav Narula ◽  
Maya Prasad ◽  
Amey Paradkar ◽  
...  

2012 ◽  
Vol 27 (6) ◽  
pp. 690-697 ◽  
Author(s):  
Stéphane Bouchet ◽  
Karine Titier ◽  
Nicholas Moore ◽  
Régis Lassalle ◽  
Basmah Ambrosino ◽  
...  

2020 ◽  
Vol 20 (2) ◽  
pp. 45-55
Author(s):  
K Prso ◽  
N Zidekova ◽  
M Dohal ◽  
I Porvaznik ◽  
M Prso ◽  
...  

AbstractTuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible Mycobacterium tuberculosis strains. Therapeutic drug monitoring presents a useful technique for the determination of plasma drug concentration to adjust appropriate dose regimes. In tuberculosis treatment, therapeutic drug monitoring is aiding clinicians in selecting an optimal therapeutic level, which is essential for the personalisation of therapy. This review is aimed at clarifying the use of therapeutic drug monitoring of the first-line antituberculosis drugs in routine clinical practice.


Sign in / Sign up

Export Citation Format

Share Document